126 related articles for article (PubMed ID: 31054880)
1. Should we smoke it for you as well? An ethnographic analysis of a drug cryptomarket environment.
Kowalski M; Hooker C; Barratt MJ
Int J Drug Policy; 2019 Nov; 73():245-254. PubMed ID: 31054880
[TBL] [Abstract][Full Text] [Related]
2. 'Nice people doing shady things': Drugs and the morality of exchange in the darknet cryptomarkets.
Masson K; Bancroft A
Int J Drug Policy; 2018 Aug; 58():78-84. PubMed ID: 29870962
[TBL] [Abstract][Full Text] [Related]
3. Safer scoring? Cryptomarkets, social supply and drug market violence.
Barratt MJ; Ferris JA; Winstock AR
Int J Drug Policy; 2016 Sep; 35():24-31. PubMed ID: 27241015
[TBL] [Abstract][Full Text] [Related]
4. Hidden wholesale: The drug diffusing capacity of online drug cryptomarkets.
Aldridge J; Décary-Hétu D
Int J Drug Policy; 2016 Sep; 35():7-15. PubMed ID: 27260863
[TBL] [Abstract][Full Text] [Related]
5. Comparing cryptomarkets for drugs. A characterisation of sellers and buyers over time.
Tzanetakis M
Int J Drug Policy; 2018 Jun; 56():176-186. PubMed ID: 29449105
[TBL] [Abstract][Full Text] [Related]
6. 'What if you live on top of a bakery and you like cakes?'-Drug use and harm trajectories before, during and after the emergence of Silk Road.
Barratt MJ; Lenton S; Maddox A; Allen M
Int J Drug Policy; 2016 Sep; 35():50-7. PubMed ID: 27157539
[TBL] [Abstract][Full Text] [Related]
7. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
Van Hout MC; Hearne E
Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
[TBL] [Abstract][Full Text] [Related]
8. Delivery dilemmas: How drug cryptomarket users identify and seek to reduce their risk of detection by law enforcement.
Aldridge J; Askew R
Int J Drug Policy; 2017 Mar; 41():101-109. PubMed ID: 28089207
[TBL] [Abstract][Full Text] [Related]
9. Nonmedical prescription psychiatric drug use and the darknet: A cryptomarket analysis.
Cunliffe J; Décary-Hêtu D; Pollak TA
Int J Drug Policy; 2019 Nov; 73():263-272. PubMed ID: 30772109
[TBL] [Abstract][Full Text] [Related]
10. The relationship between cryptomarket drug purchase, social networks and adverse drug events: A cross-sectional study.
Coney L; Peacock A; Malm A; Munksgaard R; Aldridge J; Ferris JA; Maier LJ; Winstock AR; Barratt MJ
Int J Drug Policy; 2024 Jan; 123():104258. PubMed ID: 38056221
[TBL] [Abstract][Full Text] [Related]
11. Assessing market competition and vendors' size and scope on AlphaBay.
Paquet-Clouston M; Décary-Hétu D; Morselli C
Int J Drug Policy; 2018 Apr; 54():87-98. PubMed ID: 29414490
[TBL] [Abstract][Full Text] [Related]
12. Forensic drug intelligence and the rise of cryptomarkets. Part II: Combination of data from the physical and virtual markets.
Morelato M; Broséus J; De Grazia A; Tahtouh M; Esseiva P; Roux C
Forensic Sci Int; 2018 Jul; 288():201-210. PubMed ID: 29763810
[TBL] [Abstract][Full Text] [Related]
13. Reputation transferability across contexts: Maintaining cooperation among anonymous cryptomarket actors when moving between markets.
Norbutas L; Ruiter S; Corten R
Int J Drug Policy; 2020 Feb; 76():102635. PubMed ID: 31972474
[TBL] [Abstract][Full Text] [Related]
14. Will growth in cryptomarket drug buying increase the harms of illicit drugs?
Aldridge J; Stevens A; Barratt MJ
Addiction; 2018 May; 113(5):789-796. PubMed ID: 28766792
[TBL] [Abstract][Full Text] [Related]
15. Availability of substances for use in personal vaporisers on three online cryptomarkets.
Lim CCW; Leung JKY; Connor JP; Hall WD; Gartner C; Cheng BHC; Scheurer RW; Sun T; Chan GCK
Drug Alcohol Depend; 2020 Dec; 217():108254. PubMed ID: 32979736
[TBL] [Abstract][Full Text] [Related]
16. Going international? Risk taking by cryptomarket drug vendors.
Décary-Hétu D; Paquet-Clouston M; Aldridge J
Int J Drug Policy; 2016 Sep; 35():69-76. PubMed ID: 27453145
[TBL] [Abstract][Full Text] [Related]
17. Who sells what? Country specific differences in substance availability on the Agora cryptomarket.
Van Buskirk J; Naicker S; Roxburgh A; Bruno R; Burns L
Int J Drug Policy; 2016 Sep; 35():16-23. PubMed ID: 27520115
[TBL] [Abstract][Full Text] [Related]
18. Ethics in cryptomarket research.
Martin J; Christin N
Int J Drug Policy; 2016 Sep; 35():84-91. PubMed ID: 27350571
[TBL] [Abstract][Full Text] [Related]
19. Illicit drug prices and quantity discounts: A comparison between a cryptomarket, social media, and police data.
Moeller K; Munksgaard R; Demant J
Int J Drug Policy; 2021 May; 91():102969. PubMed ID: 33041184
[TBL] [Abstract][Full Text] [Related]
20. The success rate of online illicit drug transactions during a global pandemic.
Bergeron A; Décary-Hétu D; Giommoni L; Villeneuve-Dubuc MP
Int J Drug Policy; 2022 Jan; 99():103452. PubMed ID: 34597861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
